A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell non-Hodgkin's lymphoma: Interim analysis of 18 patients.

被引：0
|
作者：
Witzig, TE
Geyer, SM
Salim, M
Inwards, DJ
Fonseca, R
Kauffnan, SH
Kurtin, P
Colgan, JP
Call, TG
Moore, D
White, WL
机构：
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Allan Blair Canc Ctr, Regina, SK, Canada
[3] Canc Ctr Kansas, Wichita, KS USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2374
引用
收藏
页码：643A / 643A
页数：1
相关论文
共 50 条
  • [1] Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes
    Smith, S. M.
    Pro, B.
    Cisneros, A.
    Smith, S.
    Stiff, P.
    Lester, E.
    Modi, S.
    Dancey, J. E.
    Vokes, E. E.
    van Besien, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, TE
    Geyer, SM
    Ghobrial, I
    Inwards, DJ
    Fonseca, R
    Kurtin, P
    Ansell, SM
    Luyun, R
    Flynn, PJ
    Morton, RF
    Dakhil, SR
    Gross, H
    Kaufmann, SH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5347 - 5356
  • [3] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kurtin, P
    Ansell, S
    Kaufmann, S
    ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
  • [4] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    BLOOD, 2009, 114 (22) : 664 - 665
  • [5] Phase II multicenter trial of pentostatin and rituximal in patients with previously treated and untreated non-Hodgkin's lymphoma (NHL)
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 642A - 643A
  • [6] Phase II safety and activity trial of two dose levels of CCI-779 in women with previously treated locally advanced or metastatic cancer-interim report.
    Chan, S
    Johnston, S
    Scheulen, ME
    Mross, K
    Berger, M
    Kirsch, T
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S132 - S132
  • [7] Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
    Redfern, Charles H.
    Guthrie, Troy H.
    Bessudo, Alberto
    Densmore, John J.
    Holman, Peter R.
    Janakiraman, Nalini
    Leonard, John P.
    Levy, Richard L.
    Just, Richard G.
    Smith, Mitchell R.
    Rosenfelt, Fred P.
    Wiernik, Peter H.
    Carter, William D.
    Gold, Daniel P.
    Melink, Teresa J.
    Gutheil, John C.
    Bender, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3107 - 3112
  • [8] A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
    F H Blackhall
    M Ranson
    J A Radford
    B W Hancock
    M Soukop
    A T McGown
    A Robbins
    G Halbert
    G C Jayson
    British Journal of Cancer, 2001, 84 : 465 - 469
  • [9] A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
    Blackhall, FH
    Ranson, M
    Radford, JA
    Hancock, BW
    Soukop, M
    McGown, AT
    Robbins, A
    Halbert, G
    Jayson, GC
    BRITISH JOURNAL OF CANCER, 2001, 84 (04) : 465 - 469
  • [10] Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.
    Ishizawa, Kenichi
    Ogura, Michinori
    Maruyama, Dai
    Abe, Yasunobu
    Ando, Kiyoshi
    Izutsu, Koji
    Terui, Yasuhito
    Yoshitaka, Imaizumi
    Fukuhara, Noriko
    Uchida, Toshiki
    Choi, Ilseung
    Ohmachi, Ken
    Yamamoto, Go
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345